A Phase 2 Trial of Zanidatamab with Chemotherapy for HER2-Positive Breast Cancer
Phase 2
125
about 4.9 years
18+
21 sites in CA, CO, FL +11
What this study is about
This trial is testing zanidatamab, a new drug, when combined with chemotherapy in people with HER2-positive early-stage breast cancer. The goal is to see if this combination is safe and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Carboplatin
- 2.Take Docetaxel
- 3.Take Paclitaxel
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carboplatin, docetaxel, paclitaxel (Taxane chemotherapy; stabilizes microtubules), pertuzumab, trastuzumab (Monoclonal antibody; targets HER2 protein on cancer cells), zanidatamab
infusion, injection, intravenous
Secondary: Event Free Survival (EFS), Number of Participants Discontinuing Study Treatment Due to TEAEs, Number of Participants with Treatment-emergent Adverse Events (TEAEs), Number of participants reporting Symptomatic Adverse Events based on European Organisation for Research and Treatment of Cancer (EORTC) Item Library, Number of participants reporting Symptomatic Adverse Events based on Patient-reported Outcome-Common Terminology Criteria for AEs (PRO-CTCAE), Overall Survival (OS)
Oncology